"This expansion in Phase I-IV clinical capability dovetails with our recent preclinical facility acquisition here in Taiwan," says Vincent Yen, President and CEO of QPS-Taiwan. "This represents the fourth cross-border acquisition QPS has made in the last six months. Clients all over the world will now have access to an even wider range of the exceptional services they have come to expect from QPS, along with an expanding global footprint."
QPS-Qualitix has an established network of prominent Taiwanese investigators at all 22 medical centers. It is the largest local CRO with broad clinical trial expertise, handling IND trials mainly focused on oncology and metabolic disorders in Taiwan, for global filing. The depth and breadth of QPS-Qualitix's experience in this important therapeutic field attracts major clients and partners including global pharmaceutical clients as well as local pharmaceutical and biotech clients from the Asia-Pacific region.
QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of Bioanalysis, Drug Metabolism and Pharmacokinetics, Toxicology, Translational Medicine, and Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Bioanalysis and Preclinical testing facilities at its Newark, DE headquarters; and facilities in Groningen, the Netherlands; Taipei, Taiwan; and Hyderabad, India. Early-phase clinical facilities are located in Springfield, MO; Taipei, Taiwan; Groningen, the Netherlands; and Hyderabad, India. Business development offices are maintained in the US, Europe, and Asia.
Qualitix is a full service CRO based in Taipei, Taiwan and Shanghai, China, an
|SOURCE QPS, LLC|
Copyright©2010 PR Newswire.
All rights reserved